The Tumour Found During an Appendectomy: Appendiceal Neoplasms and Pseudomyxoma
An appendix comes out overnight for what everyone took to be appendicitis. The operation goes well. Then a pathology report arrives a week later and describes something nobody was looking for: a tumour, named in words the discharge summary never used. Nothing hurts. No appointment is booked. The report is the whole event, and what happens next is decided almost entirely by how carefully a few lines of it are read. Reading them down to the cause instead of stopping at the label is what Healz does with a report like this.
This post walks the finding from the top: why appendiceal tumours are nearly always found this way, what the current names mean and which retired ones still turn up in real reports, what pseudomyxoma peritonei actually is, and the specific wording that guidelines key their recommendations to.
Why the pathology report is the first news
Almost nobody is diagnosed with an appendiceal tumour before surgery. The appendix comes out for suspected appendicitis, the specimen goes to the laboratory, and the tumour is found there. The PSOGI and EURACAN clinical practice guidelines put the rate for epithelial appendiceal tumours at 0.7% to 1.7% of appendicectomy specimens removed for suspected appendicitis (European Journal of Surgical Oncology, 2021). A 2026 review in Annali Italiani di Chirurgia gives a similar range and notes the reported incidence has been rising.
One pattern inside that is worth knowing: complicated appendicitis, meaning perforation or an abscess, is associated with a higher chance of an underlying tumour, with reported rates ranging from 5% to 29% across series (Annali Italiani di Chirurgia, 2026). The same review lists what raises suspicion: older age, persistent or recurrent symptoms, an appendiceal abscess, an unusually prolonged inflammatory course.
Ask Healz.
One chat instead of ten apps. 1M+ rare cases checked. The root cause, not the label. Private.
For appendiceal neuroendocrine tumours the incidental route is even more absolute: a 2023 review in Current Treatment Options in Oncology describes the diagnosis as nearly always incidental during an appendectomy done for other reasons. Here, learning to read a pathology report is not academic. It is the only document in the room.
The names on the report, old and new
The terminology was rewritten and the old words did not disappear, so a reader can hold two reports that look like different diseases.
Under the 5th edition of the WHO Classification of Digestive System Tumours (2019), appendiceal neoplasms fall into four main groups: neuroendocrine tumours, mucinous neoplasms, goblet cell adenocarcinomas, and non-mucinous adenocarcinomas. The mucinous group is then split by cytological grade and by whether there is infiltrative invasion, into low-grade appendiceal mucinous neoplasm (LAMN), high-grade appendiceal mucinous neoplasm (HAMN), and mucinous adenocarcinoma (as summarised in Annali Italiani di Chirurgia, 2026).
The retired names are the ones that confuse. A 2016 consensus developed through the Peritoneal Surface Oncology Group International, published by Carr and colleagues in the American Journal of Surgical Pathology, adopted LAMN, proposed HAMN for lesions with high-grade cytological atypia but no infiltrative invasion, reserved mucinous adenocarcinoma for lesions showing infiltrative invasion, and stated that cystadenoma was no longer recommended. Mucocele is a different kind of word again: it describes the gross appearance of an appendix distended with mucin, and a 2017 review in The Oncologist notes LAMN was introduced to replace it. Goblet cell tumours were renamed too. The WHO 5th edition dropped goblet cell carcinoid in favour of goblet cell adenocarcinoma, and the 2026 Annali Italiani di Chirurgia case series notes it is now classified separately from both mucinous and non-mucinous adenocarcinomas. So mucocele, cystadenoma and cystadenocarcinoma sitting beside LAMN is not a contradiction. It is two vocabularies describing one appendix.
Pseudomyxoma peritonei is a syndrome, not a cell type
This is the term that frightens people most and is explained least. Pseudomyxoma peritonei is a rare peritoneal malignancy with an estimated incidence of one to three per million people a year, most commonly originating from a perforated epithelial tumour of the appendix, and it is characterised by diffuse progressive mucinous ascites (PSOGI/EURACAN, 2021). The mucin accumulates gradually, which is why many people have no early symptoms and the common complaints are bloating, distension and pain.
The conceptual point is that the term names a clinical picture rather than one tumour cell. The PSOGI/EURACAN guideline is explicit that appendiceal pseudomyxoma is a clinical entity incorporating two malignant components, the appendiceal primary and the secondary peritoneal disease, each with its own histological subclassification, sometimes discordant. Some authors have argued the phrase should be reserved for the macroscopic appearance of mucinous ascites and dropped as a histological diagnosis, but the 2016 PSOGI consensus kept it as one and graded it instead. The peritoneal disease carries its own graded tiers: acellular mucin as a separate category, then low-grade mucinous carcinoma peritonei, high-grade, and high-grade with signet ring cells (Carr and colleagues, 2016). Reading the peritoneal grade and the appendiceal grade as two separate facts is what makes the report legible. Our companion piece on mucinous ascites and peritoneal spread covers what mucinous fluid in the abdomen means more broadly.
The words in the report that carry the weight
Guidelines here are written against a short list of specific phrases, which is why under-reading the report costs so much.
Three findings do most of the work. Whether the appendix was perforated or intact. Whether mucin outside the appendix is acellular (no tumour cells) or cellular (cells present). And whether the resection margin is clear, including at the base where the appendix joins the bowel. The PSOGI and EURACAN recommendations are worded in exactly those terms. For a non-perforated LAMN with a clear margin and no sign of residual disease, the panel's position is that there is no role for an additional right-sided hemicolectomy. For a perforated LAMN with acellular or cellular mucin in the periappendiceal visceral peritoneum, the position shifts: cytoreductive surgery with heated intraperitoneal chemotherapy could be considered.
The 2026 Annali Italiani di Chirurgia case series and literature review puts the same split plainly: LAMNs with negative margins and no perforation or peritoneal involvement can be managed with appendectomy alone, while appendiceal adenocarcinoma generally prompts an oncological right hemicolectomy with lymphadenectomy because the risk of nodal spread is substantially higher. In its own four cases, a positive margin at the appendiceal orifice was what turned one appendectomy into a completion hemicolectomy; a goblet cell adenocarcinoma with clear margins prompted another. None of this is a prescription for one person, and the literature is openly unsettled in places. It is a map of which words the next conversation turns on.
When the tumour is neuroendocrine instead
An appendiceal neuroendocrine tumour is a separate story, and size is the headline number. The NCI PDQ summary on gastrointestinal neuroendocrine tumours, health professional version (updated 05/09/2025), states that these tumours can be consistently cured by appendectomy for the roughly 90% that are smaller than 1 cm and not at the appendiceal base, that treatment is controversial for tumours measuring 1 to 2 cm, and that tumours larger than 2 cm require right-sided hemicolectomy and ileocaecal lymphadenectomy because of the metastasis risk. For the 1 to 2 cm group it adds that hemicolectomy may be appropriate where there is invasion into the mesoappendix, residual tumour at the margins, or nodal metastases.
The grey zone is genuinely grey. The 2026 Annali Italiani di Chirurgia review notes that NANETS and ENETS guidance supports appendectomy alone for tumours under 1 cm and for 1 to 2 cm lesions without adverse features, while NCCN guidance supports appendectomy alone for all tumours under 2 cm, and that large database analyses have not shown a survival benefit for hemicolectomy under 2 cm even with high-risk pathology. The features usually counted as adverse are location at the base of the appendix, grade G2, mesoappendiceal or lymphovascular invasion, a raised mitotic index and a Ki-67 above 3%. Our piece on neuroendocrine tumours and the carcinoid label goes into how these tumours behave elsewhere in the gut.
What the workup after an incidental finding looks like
Once a tumour is on the report, the questions are what else is there and where it gets treated.
Imaging comes first: the PSOGI and EURACAN panel recommends computed tomography as the preferred diagnostic imaging modality for appendiceal pseudomyxoma. Tumour markers come next, and their role is narrower than assumed. The same guideline makes a baseline serum CEA and CA 19-9 mandatory in the preoperative workup of appendiceal pseudomyxoma, with CA 125 as optional. They are burden and trend markers, not diagnoses: a 2022 multi-institutional analysis in the Journal of Gastrointestinal Surgery found elevated preoperative markers signalled more disease but did not independently predict survival. Colonoscopy is recommended before cytoreductive surgery to exclude a second primary, given the known risk of synchronous colorectal lesions (PSOGI/EURACAN, 2021).
Then the decision that matters most. For overt appendiceal pseudomyxoma, the PSOGI and EURACAN recommendation on cytoreductive surgery with heated intraperitoneal chemotherapy is conditioned on the patient being fit for major surgery, the disease being resectable, and the treatment being given in a specialised peritoneal surface malignancy centre. The referral is part of the treatment, not an administrative step after it.
How Healz reads an appendix tumour that nobody expected
The operative note, the pathology wording and the follow-up scan have to be read against each other, because the decision that follows depends on all three. In most care those three documents sit in three different systems. Healz holds them in one place, one chat, not ten apps. Frontier AI works the whole case and reads what you upload, lab results, scan reports, pathology PDFs and photos, in a private encrypted library.
Healz is equipped with root-cause technology, which is what this finding needs. It does not stop at the first label on the report. It asks what a rushed post-operative phone call skips: perforated or intact, acellular or cellular mucin, clear margin or involved base, which vocabulary this pathologist is using. It cross-checks the case against more than a million rare cases, and searches current studies and trials for the specific picture rather than the general diagnosis. Healz's memory pulls the medical facts out of every upload, dates them, keeps the abnormal values up front and connects this month's scan to the operative note from two months ago. As a cancer ai used to read pathology report wording, it can also produce ready documents in the chat, such as a PDF of questions for the next appointment. You can bring a board-certified doctor into the same chat for a second opinion.
Frequently asked questions
- What does LAMN mean on a pathology report?
LAMN stands for low-grade appendiceal mucinous neoplasm: a mucinous tumour of the appendix with low-grade cytology and no infiltrative invasion. The term was adopted in the 2016 PSOGI consensus in the American Journal of Surgical Pathology, which also stated cystadenoma was no longer recommended.
- Is pseudomyxoma peritonei cancer?
It is classified as a rare peritoneal malignancy, most commonly from a perforated epithelial tumour of the appendix, at an estimated one to three cases per million people a year (PSOGI/EURACAN, 2021). The term names a clinical picture rather than a single tumour cell, and the peritoneal disease is graded in its own right, from acellular mucin up to high-grade disease with signet ring cells.
- What does acellular mucin mean?
It means mucin found outside the appendix with no tumour cells in it, as opposed to cellular mucin, which contains cells. The 2016 PSOGI consensus treats acellular mucin as its own category rather than as pseudomyxoma peritonei, and the PSOGI and EURACAN recommendations are written separately for the two, which is why the distinction is in the report at all.
- How do you read a pathology report after an appendectomy?
Three things carry most of the weight: the tumour type and grade, whether the appendix was perforated, and whether the resection margin is clear, including at the base. If mucin is described outside the appendix, acellular or cellular is the next line to find. Old and current names coexist, so mucocele beside LAMN is one tumour in two vocabularies.
An appendix removed for appendicitis can return a report about a disease nobody was looking for, and that week the wording is diagnosis, staging and referral at once, which is why it is read down to the cause and never skimmed for the label.
Written by Healz Team · Filed under Health Insights
